Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill
Skyharbour Commences Drilling at the Getty East Uranium Joint Venture with Partner Denison Mines at the Russell Lake Project Area
